Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Recludix Pharma to Present at RBC Capital Markets Global Healthcare Conference

globenewswire.com
LLY Mentioned as a former employer of Recludix Pharma's management team, indicating industry experience but no direct company news. SNY Sanofi is mentioned as a partner in a development and commercialization agreement with Recludix Pharma, but no specific news about Sanofi itself is provided.

Recludix Pharma to Present at RBC Capital Markets Global Healthcare Conference SAN DIEGO, May 18, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present an overview of the company at the RBC Capital Markets Global Healthcare Conference in New York, NY. The company’s presentation will be on Wednesday, May 20, 2026, at 2:35 p.m. Eastern Time.

To access the live and archived webcast of the presentation, visit the News & Events page of the company’s website at https://recludixpharma.com/news-events/#events.

About Recludix

Recludix is a clinical-stage company with leading, innovative platform approaches to discover and develop potent and selective inhibitors of challenging protein targets. The company’s management team includes industry veterans with a track record of success, including former leaders of Seagen, Blueprint Medicines, and Lilly. Recludix has developed a unique drug discovery platform that integrates custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity. The company is employing this approach first in the development of SH2 domain inhibitors.

Recludix is conducting a Phase 1 study of REX-8756 (also known as SAR448755), an oral inhibitor of STAT6, in a strategic development and commercialization partnership with Sanofi where Recludix has the option to participate in an equal U.S. profit/loss share. Abnormal activation of STAT6 is found in inflammatory diseases, such as atopic dermatitis, asthma, chronic obstructive pulmonary disease and chronic spontaneous urticaria.

Recludix is also advancing a potential first-in-class BTK SH2 domain inhibitor for B cell or mast cell-driven I&I diseases, as well as additional discovery programs. Recludix was named a 2024 Fierce 15 biotech company. For more information, please visit the company’s website at https://recludixpharma.com.

Recludix Contacts

Matt Caldemeyer

Chief Business Officer

mcaldemeyer@recludix.com

Alexandra Santos

asantos@wheelhouselsa.com

Aljanae Reynolds

areynolds@wheelhouselsa.com